Downloading...
Download

Gilead

Gilead Sciences (GILD) Soars 4.93% on Strong Q4 Earnings ReportsGilead Sciences (NASDAQ: NASDAQ:GILD ) is making waves in the biotech sector after delivering a stellar fourth-quarter earnings report that not only crushed Wall Street expectations but also set the stage for a promising 2025. The stock surged 4.50% in premarket trading on Wednesday, signaling strong investor confidence in the company’s growth trajectory. Quarter and Optimistic Guidance Gilead’s Q4 earnings report was nothing short of impressive. The company posted adjusted earnings of $1.90 per share, a 10.5% year-over-year increase, and handily beat analysts’ estimates of $1.74. Revenue climbed 6% to $7.57 billion, surpassing the consensus forecast of $7.15 billion. HIV Franchise Shines Bright Gilead’s HIV portfolio remains its crown jewel. Biktarvy, the company’s flagship HIV treatment, generated $3.8 billion in sales, up 21% year-over-year and well ahead of the $3.47 billion forecast. Descovy, another HIV drug, also outperformed expectations, with sales rising 21% to $616 million. Combined, Gilead’s HIV product sales reached $5.45 billion, up 16% from the previous year. Looking ahead, Gilead is poised to expand its HIV franchise further with the anticipated mid-2025 launch of lenacapavir, a twice-yearly injectable for HIV prevention. The U.S. Food and Drug Administration (FDA) is expected to make a decision on the drug by mid-2024, and its approval could be a significant growth catalyst. Oncology and Liver Disease: Steady Growth Gilead’s oncology and liver disease segments also contributed to the strong quarter. Sales of its cell therapies for cancer treatment rose 5% to $488 million, beating expectations of $476 million. Trodelvy, a cancer drug, saw sales jump 19% to $355 million, surpassing the $324 million forecast. Liver disease treatments brought in $719 million, up 4% year-over-year. Veklury: The Only Blemish The only downside in Gilead’s report was Veklury, its COVID-19 treatment. Sales plummeted 53% to $337 million due to lower hospitalizations, particularly in the U.S. Upbeat 2025 Guidance Gilead’s bullish outlook for 2025 further fueled investor optimism. The company expects adjusted earnings of $7.70 to $8.10 per share on product sales of $28.2 billion to $28.6 billion. The midpoint of this guidance exceeds analysts’ estimates of $7.61 per share and $28.35 billion in revenue. Technical Analysis From a technical perspective, Gilead’s stock is showing strong bullish signals. As of Wednesday’s premarket trading, GILD is up 4.93%, poised to form a gap-up pattern upon market open. Key Levels to Watch - Resistance: A breakout above the 1-month high of $100 could serve as a critical catalyst for a sustained bullish run. This level represents a psychological barrier, and a decisive move above it could attract more buyers. - Support: In the event of a pullback, immediate support lies at the 65% Fibonacci retracement level, which aligns with the $92 mark. This level could act as a springboard for renewed upward momentum. RSI Indicates Room for Growth The Relative Strength Index (RSI) stands at 55, indicating that the stock is neither overbought nor oversold. This suggests there is ample room for further upside, especially if the broader market sentiment remains favorable. Conclusion Gilead Sciences (GILD) is firing on all cylinders, with a strong Q4 earnings beat, robust guidance for 2025, and a promising pipeline. The company’s leadership in the HIV market, coupled with its growing presence in oncology and liver disease, positions it well for long-term growth. From a technical standpoint, the stock is primed for a breakout, with key resistance and support levels offering clear markers for traders and investors.
NASDAQ:GILDLong
by DEXWireNews
Gilead Sciences (GILD): First Take Profit in a High RangeGilead Sciences is now back trading at the high end of its range, and we’ve decided to take our first profit here. It’s crucial to respect range-bound trading, and there is a strong possibility of a pullback at this point. However, we don’t expect this pullback to reach the lower end of the range again but rather settle in the middle. If NASDAQ:GILD reclaims this range high, it could provide even more upside and new opportunities. We are also raising our stop loss to $65.80 to lock in gains. Gilead serves as our "natural hedge" against broader risk-on market conditions, and with a 40% bounce from the range low at the same time the S&P 500 is hitting new all-time highs, it’s clear that Gilead can benefit as well. We’re keeping a close eye on this stock, and if another opportunity arises, we’ll be ready to act.
NASDAQ:GILDLong
by freeguy_by_wmc
Gilead's Trodelvy Faces Setback in Lung Cancer Trial In a recent announcement, Gilead Sciences ( NASDAQ:GILD ) disclosed disappointing results from a late-stage trial evaluating its antibody-drug conjugate, Trodelvy, in second-line treatment for advanced non-small cell lung cancer (NSCLC). The Phase 3 study, aiming to expand Trodelvy's applications, did not meet its primary goal of significantly improving survival for previously treated patients. Despite a noted three-month survival benefit for a subgroup, the overall outcome fell short of statistical significance. This setback raises questions about Trodelvy's potential in lung cancer and underscores the challenges in developing effective treatments for this complex disease. The Trial and Its Implications: The trial involved 603 patients with metastatic or advanced NSCLC who had experienced disease progression despite standard platinum-based chemotherapy and checkpoint inhibitor treatment. Gilead reported that patients receiving Trodelvy exhibited longer survival compared to those on chemotherapy, but the difference did not reach statistical significance. Notably, a subgroup of patients who did not respond to their last checkpoint inhibitor treatment showed a more than three-month survival benefit. Gilead plans to discuss these results with regulators and present the full data at an upcoming medical meeting, indicating a commitment to transparent communication and a thorough examination of the findings. Exploring Trodelvy's Potential: Despite the setback, Gilead ( NASDAQ:GILD ) remains optimistic about Trodelvy's potential in metastatic NSCLC. The company emphasizes the drug's positive impact on a specific patient subgroup and expresses confidence in Trodelvy's broader lung cancer clinical development program. Gilead's Chief Medical Officer, Merdad Parsey, highlights ongoing Phase 2 and 3 trials investigating Trodelvy in combination with Keytruda as an initial treatment for NSCLC patients. The company's dedication to understanding the drug's effects and exploring potential pathways reflects a commitment to advancing cancer care. Trodelvy's Safety Profile and Current Approvals: Gilead ( NASDAQ:GILD ) reassures stakeholders by affirming that Trodelvy's safety profile aligns with prior studies, with common adverse events being neutropenia (low white blood cell counts) and diarrhea. It's worth noting that Trodelvy is already approved by U.S. regulators for specific advanced breast cancer and bladder cancer indications. In the first nine months of the previous year, Gilead reported sales of $765 million for Trodelvy, attesting to its commercial success in the approved indications. Future Prospects and Challenges: Despite the setback in the second-line lung cancer trial, Gilead remains resilient in its pursuit of innovative solutions for oncology. The ongoing front-line Phase 3 trial combining Trodelvy with Keytruda suggests a strategic focus on exploring novel treatment approaches. However, as emphasized by Parsey, results from this trial are not expected for at least a couple of years, highlighting the prolonged timeline inherent in clinical research. Conclusion: Gilead's ( NASDAQ:GILD ) recent trial results for Trodelvy in second-line NSCLC treatment present a nuanced narrative of challenges and opportunities in the evolving landscape of cancer therapeutics. The company's commitment to transparency, ongoing research, and exploration of combination therapies underscores the complexity of addressing lung cancer, one of the most formidable challenges in oncology. As the full dataset becomes available and discussions with regulators unfold, stakeholders will eagerly anticipate the next chapter in Trodelvy's journey, hoping for breakthroughs that could reshape the future of lung cancer treatment.
NASDAQ:GILD
by DEXWireNews
GILD Gilead Sciences Options Ahead of EarningsIf you haven`t bought GILD on the Remdesivir approval: Then analyzing the options chain and the chart patterns of GILD Gilead Sciences prior to the earnings report this week, I would consider purchasing the 80usd strike price in the money Calls with an expiration date of 2024-1-19, for a premium of approximately $4.25. If these options prove to be profitable prior to the earnings release, I would sell at least half of them. Looking forward to read your opinion about it.
NASDAQ:GILDLong
by TopgOptions
Let's short Gilead! GILDXABCD, ABC patterns at play. Confirmation via eMA, candlestick pattern. Here we go. We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in purple with invalidation in red. Confirmation level, where relevant, is a pink dotted, finite line. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels that the market will go to. Having said that, the market will always do what it wants and always has a mind of its own. Therefore, none of this is financial advice, so do your own research and rely only on your own analysis. Trading is a true one man sport. Good luck out there and stay safe.
NASDAQ:GILDShort
by Rykin_Capital
Shorting Gilead. GILDIndeed. B Wave in a zigzag form appears to be completed. We are going down to one extent to another. We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in purple with invalidation in red. Confirmation level, where relevant, is a pink dotted, finite line. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels that the market will go to. Having said that, the market will always do what it wants and always has a mind of its own. Therefore, none of this is financial advice, so do your own research and rely only on your own analysis. Trading is a true one man sport. Good luck out there and stay safe.
NASDAQ:GILDShort
by Rykin_Capital
GILD - The Sleeping Giant - Trend ReversalGILD - The Sleeping Giant - Trend Reversal ___________________ ENTRY = 56.56 Double Bottom - +64 confirmation 1st Target = [email protected] 2nd Target = [email protected] 3rd Target = [email protected] HOLD Target = [email protected]+ JAN22 Call Leaps Still cheap ________________________________________________________________________________________________________________________ This content is for informational and educational purposes only. This is not in any way, shape or form financial or trading advice. Good luck, happy trading and stay chill, 2degreez
NASDAQ:GILDLong
by UnknownUnicorn7216011
BUY $GILD - NR Picks Dec 06EN: Gilead Sciences, Inc. is an American biopharmaceutical company based in Foster City, California, that researches, develops and markets drugs in under-explored areas of medical need in the United States, Europe, and internationally. Its products include treatments for human immunodeficiency virus (HIV) infection and liver disease. It is currently at a key level of the last three months that could indicate a change in trend, being able to surpass its resistance of 61 - 62 and would reach the sell zone. It should be mentioned that in recent years its dividend has increased from 2% in 2015 to 4% in 2020. December 14 is its cutoff date and it is scheduled to pay dividends on December 30. In terms of its income structure, products related to HIV treatment represent 70% of its income, its main market being the United States. ES: Gilead Sciences, Inc. es una compañía biofarmacéutica estadounidense con sede en Foster City, California, que investiga, desarrolla y comercializa medicamentos en áreas de necesidades médicas poco exploradas en los Estados Unidos, Europa e internacionalmente. Sus productos incluyen tratamientos contra la infección por el virus de la inmunodeficiencia humana (VIH) y enfermedades hepáticas. Actualmente se encuentra en un nivel clave de los últimos tres meses que podría indicar un cambio de tendencia, pudiendo sobrepasar su resistencia de los 61 – 62 y alcanzaría la zona de venta. Cade mencionar que en los últimos años ha ido incrementado su dividendo pasando de 2% en el 2015 a un 4% en el 2020. El 14 de Diciembre es su fecha de corte y tiene programado pagar dividendos el 30 de Diciembre. En cuanto a su estructura de ingresos los productos relacionados al tratamiento del VIH representan un 70% de sus ingresos siendo su mercado principal Estados Unidos.
NASDAQ:GILDLong
by NewroadTrader
1
Entry of the gladiatorsWonderful bullish news! There is a vaccine. The economic activity can soon go back to normal. The question now is how do we make it obligatory? Crazy antivax conspiracy theorists are saying that because it is a rushed & untested vaccine and entirely new technology that affects ARN and contains heavy metals that can breach the blood-brain barrier we should let people choose if they want to take it. Haha ridiculous, they probably think the earth is flat am I right? We have no other choice, if we do not all take the vaccines millions will die, they do not only put themselves at risk by refusing to take it but they also put others at risk. You know why we can trust pharmaceutical giants even though there is a major scandal every 2 weeks where they caused harm to make money? Because there are now laws that make them immune against any consequences if there are long term negative effects. Isn't that great? So now they can work with a clear mind and only focus on producing a vaccine as fast as possible to maximize profit without having to worry about any annoying long term side effect! And officials clearly have our best interest at mind even though they might have a few millions in conflict of interests. Why do I know this? Well the fact that Philippines have kicked out and want to punish Sanofi for selling to them an extremely dangerous & inefficient vaccine against Dengue, while the European Union have fully allowed this vaccine which we'll have the pleasure to get access to if we get a Dengue outbreak in Europe because they do not believe in conspiracies and want people to be healthy. Of course Ursula has our best interests at mind. So does Joe. The Philippines are just conspiracy nuts and anti-China racists obviously. Ok yes, every single child out of hundreds that took the Dengvaxia dropped dead and so what? Never heard of coincidences? Just because there is a correlation does not mean there is a crazy conspiracy theory silly. Children die all the time in the Philippines as it is a third world country. People are losing their minds simply because Germany has passed an infection protection law, ridiculous, they say it reminds them of the 1933 enabling act. It's not the same silly, it is called "infection protection law" not "enabling act to solve the distress of the people", see? Entirely different. Schlomo Goldstein is hiding in a cellar; this is insane! People have gone completely paranoiac! And they don't believe in science and facts but primitive conspiracies. Schlomo should get on that train for his own good. The stories that "people are never seen again" and "the german government is sending all jews to concentration camps", how crazy does this sound to you? How can people imagine such insanity? Independent fact checkers have been to Auschwitz and Dachau and gave these vacation camps a 5 ✡️ out of 5. The official claim from our independent fact checking sources is "The vacation camps of Auschwitz and Dachau are wonderful places and all of our independent fact checkers financed by facebook had a great time there, we are giving them a full recommendation". See? There is nothing to worry about. We are on our way to a great time of peace, prosperity, and health.
NASDAQ:GILD
by MrRenev
5
GILD Gilead upside potentialReuters Adage Capital Partners GP LLC Dissolves Share Stake In Moderna, Takes In Gilead Sciences! Reuters: Germany requests 5% of EU supply of remdesivir Germany has requested around 5% of the supply of remdesivir under a six-month European Union supply deal, its health ministry said on Monday, despite criticism of the deal due to a lack of evidence about the antiviral drug's effectiveness in treating COVID-19. A course of treatment for COVID-19 requires six doses and costs 2,070 euros ($2,407) per treatment, under the terms of the deal. The indicators are showing buy signals on every timeframe! If you are interested to test some amazing BUY and SELL INDICATORS, which give the signal at the beginning of the candle, not at the end of it, just leave me a message.
NASDAQ:GILDLong
by TopgOptions
2